Targeted Oncology4 天
Amivantamab/Lazertinib Maintains OS Benefit in EGFR+ NSCLC
During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...
Bristol sees annual $1.5B in cost savings by end of 2025
Bristol Myers Squibb (NYSE:BMY) said that ongoing initiatives to cut costs will lead to the realization of $1.5B in annual ...